Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

@article{James2014LenalidomideAR,
  title={Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.},
  author={Danelle Frances James and Lillian L Werner and Jennifer Rose Brown and William G Wierda and Jacqueline C Barrientos and Januario E. Castro and Andrew Greaves and Amy J. Johnson and Laura Z. Rassenti and Kanti R Rai and Donna S Neuberg and Thomas J. Kipps},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 19},
  pages={2067-73}
}
PURPOSE Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic leukemia (CLL). In preclinical models, lenalidomide acted synergistically with rituximab. The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment-naive patients. PATIENTS AND METHODS Lenalidomide was initiated at 2.5 mg/day and was escalated based on treatment tolerability to a maximum of 10 mg/day, for 21 days/cycle, for a maximum of seven cycles… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…